NCT06422728 The Effectiveness of Transdiagnostic CBT Protocol on Anxiety Disorders
| NCT ID | NCT06422728 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ibn Haldun University |
| Condition | Anxiety Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-06-20 |
| Primary Completion | 2024-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-06-20 with a primary completion date of 2024-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The transdiagnostic approach argues that the common features are needed to be taken into account \[e.g. distress intolerance (DI), intolerance of uncertainty (IU), worry)\] underlying emotional disorders rather than evaluating them separately due to the fact that the dissection of anxiety disorders has increased with each emerging version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), in which the classification of anxiety disorders resulted in an increased number of intervention protocols for each disorder. This also caused an increase of comorbidity among anxiety disorders. Transdiagnostic approach offers a unified protocol (UP) for strengthening the common features, and thereby both preventing the emergence of emotional disorders or intervening the symptom severity of emotional disorders, which can be applied to different types of emotional disorders. The main aim of this study is to develop a UP which is planned to be applied as a group therapy. The UP will include interventions developing the levels of common transdiagnostic features (DI, IU and worry). The study's second aim is to investigate the effect of the developed UP on DI, IU and worry. The third one is to search the effect of the developed UP on symptom severity levels of anxiety disorders. Fourthly, this study will search if the levels of transdiagnostic common features (DI, IU and worry) will predict the levels of symptom severity of anxiety disorders'.
Eligibility Criteria
Inclusion Criteria: * Being diagnosed with at least one of the following disorders in the pre-interview (SCID 5 interview for diagnosis): generalized anxiety disorder (GAD), panic disorder (PD), social anxiety disorder (SAD) or anxiety disorder not otherwise specified (NOS). Exclusion Criteria: * Active substance use or having a psychiatric history related to substance use * Having a co-diagnosis of psychotic disorders or bipolar disorders * Receiving active psychotherapy support * Being not graduated from primary school
Contact & Investigator
Iclal AYDIN, MA
PRINCIPAL INVESTIGATOR
İbn Haldun University
Frequently Asked Questions
Who can join the NCT06422728 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Anxiety Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06422728 currently recruiting?
Yes, NCT06422728 is actively recruiting participants. Contact the research team at iclalaydin@stu.ihu.edu.tr for enrollment information.
Where is the NCT06422728 trial being conducted?
This trial is being conducted at Zeyti̇nburnu, Turkey (Türkiye).
Who is sponsoring the NCT06422728 clinical trial?
NCT06422728 is sponsored by Ibn Haldun University. The principal investigator is Iclal AYDIN, MA at İbn Haldun University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.